We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Exact Sciences (EXAS) is an Intriguing Medical Stock to Watch After Q3 Earnings
Read MoreHide Full Article
Reporting favorable Q3 results on Monday evening, Exact Sciences (EXAS - Free Report) is an intriguing stock to watch among the Zacks Rank #1 (Strong Buy) list.
Recognized as a leader in medical diagnostics, the upside potential for Exact Sciences stock has been lifted by its improved operational and financial performance. Correlating with such, EXAS spiked nearly +4% on Tuesday and is now up more than +20% in 2025.
Image Source: Zacks Investment Research
High Demand for Exact Sciences Cancer Screening Tests
Exact Sciences is seeing surging demand for its non-invasive at-home screening test, Cologuard, which detects both cancerous and precancerous cells for colorectal cancer. Adding further momentum to its diagnostic portfolio was the launch of CancerGuard, a multi-cancer early detection test, with Exact Sciences' Screening revenue jumping 22% year over year to $666 million. Overall, Exact Sciences Q4 sales rose 20% to $850.74 million and comfortably exceeded estimates of $810.45 million.
On the bottom line, Exact Sciences posted adjusted EPS of $0.24, beating expectations of $0.13 and climbing from an adjusted loss of $0.21 per share in Q3 2024. On a GAAP basis, Exact Sciences posted a much narrower net loss of $19.6 million versus a loss of $70 million a year ago. It’s also noteworthy that Exact Sciences' Adjusted EBITDA was up 37% YoY to $135 million with a margin expansion of 200 basis points to 16%.
Exact Sciences Strong Free Cash Flow
Bolstering improvements to its financialhealth, it’s important to note the cash flow improvements that were also highlighted in Exact Sciences' Q3 report.
In this regard, Exact Sciences' free cash flow spiked 69% during Q3 to $190 million, with the company seeing record operating cash flow of $220 million.
Exact Sciences Favorable Guidance
Raising its full-year fiscal 2025 guidance, Exact Sciences now expects annual sales to hit a new peak of between $3.22 billion-$3.23 billion, up from a previous range of $3.13 billion-$3.17 billion. This would reflect over 16% growth from FY24 sales of $2.76 billion.
Image Source: Zacks Investment Research
Bottom Line
Record-breaking revenue growth, improved profitability, and the successful launch of its new multi-cancer detection test are leading to bullish sentiment for Exact Sciences stock, which was already benefiting from a positive trend of earnings estimate revisions (EPS) ahead of its Q3 report.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Exact Sciences (EXAS) is an Intriguing Medical Stock to Watch After Q3 Earnings
Reporting favorable Q3 results on Monday evening, Exact Sciences (EXAS - Free Report) is an intriguing stock to watch among the Zacks Rank #1 (Strong Buy) list.
Recognized as a leader in medical diagnostics, the upside potential for Exact Sciences stock has been lifted by its improved operational and financial performance. Correlating with such, EXAS spiked nearly +4% on Tuesday and is now up more than +20% in 2025.
Image Source: Zacks Investment Research
High Demand for Exact Sciences Cancer Screening Tests
Exact Sciences is seeing surging demand for its non-invasive at-home screening test, Cologuard, which detects both cancerous and precancerous cells for colorectal cancer. Adding further momentum to its diagnostic portfolio was the launch of CancerGuard, a multi-cancer early detection test, with Exact Sciences' Screening revenue jumping 22% year over year to $666 million. Overall, Exact Sciences Q4 sales rose 20% to $850.74 million and comfortably exceeded estimates of $810.45 million.
On the bottom line, Exact Sciences posted adjusted EPS of $0.24, beating expectations of $0.13 and climbing from an adjusted loss of $0.21 per share in Q3 2024. On a GAAP basis, Exact Sciences posted a much narrower net loss of $19.6 million versus a loss of $70 million a year ago. It’s also noteworthy that Exact Sciences' Adjusted EBITDA was up 37% YoY to $135 million with a margin expansion of 200 basis points to 16%.
Exact Sciences Strong Free Cash Flow
Bolstering improvements to its financial health, it’s important to note the cash flow improvements that were also highlighted in Exact Sciences' Q3 report.
In this regard, Exact Sciences' free cash flow spiked 69% during Q3 to $190 million, with the company seeing record operating cash flow of $220 million.
Exact Sciences Favorable Guidance
Raising its full-year fiscal 2025 guidance, Exact Sciences now expects annual sales to hit a new peak of between $3.22 billion-$3.23 billion, up from a previous range of $3.13 billion-$3.17 billion. This would reflect over 16% growth from FY24 sales of $2.76 billion.
Image Source: Zacks Investment Research
Bottom Line
Record-breaking revenue growth, improved profitability, and the successful launch of its new multi-cancer detection test are leading to bullish sentiment for Exact Sciences stock, which was already benefiting from a positive trend of earnings estimate revisions (EPS) ahead of its Q3 report.